ES2205231T3 - Procedimiento de tratamiento de la hipersensibilidad de tipo i que utilizan monofosforil lipido a. - Google Patents
Procedimiento de tratamiento de la hipersensibilidad de tipo i que utilizan monofosforil lipido a.Info
- Publication number
- ES2205231T3 ES2205231T3 ES97926449T ES97926449T ES2205231T3 ES 2205231 T3 ES2205231 T3 ES 2205231T3 ES 97926449 T ES97926449 T ES 97926449T ES 97926449 T ES97926449 T ES 97926449T ES 2205231 T3 ES2205231 T3 ES 2205231T3
- Authority
- ES
- Spain
- Prior art keywords
- allergen
- mla
- ige
- hypersensitivity
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title claims description 16
- 206010020751 Hypersensitivity Diseases 0.000 title abstract description 30
- 208000026935 allergic disease Diseases 0.000 title abstract description 20
- 238000000034 method Methods 0.000 title abstract description 16
- 230000009610 hypersensitivity Effects 0.000 title abstract description 8
- 239000013566 allergen Substances 0.000 claims abstract description 94
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims abstract description 19
- 206010045240 Type I hypersensitivity Diseases 0.000 claims abstract description 17
- 208000001718 Immediate Hypersensitivity Diseases 0.000 claims abstract description 16
- 230000009959 type I hypersensitivity Effects 0.000 claims abstract description 16
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 58
- 239000002158 endotoxin Substances 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000029142 excretion Effects 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 101000750404 Phoneutria keyserlingi CRISP-1 Proteins 0.000 claims 1
- 239000002919 insect venom Substances 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 239000013573 pollen allergen Substances 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 231100000611 venom Toxicity 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 17
- 229960005486 vaccine Drugs 0.000 abstract description 6
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 2
- 102000018358 immunoglobulin Human genes 0.000 abstract description 2
- 150000002632 lipids Chemical class 0.000 abstract description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 11
- 229960004784 allergens Drugs 0.000 description 10
- 238000000586 desensitisation Methods 0.000 description 10
- 238000009169 immunotherapy Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000007815 allergy Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 208000030961 allergic reaction Diseases 0.000 description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 210000003630 histaminocyte Anatomy 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000005313 fatty acid group Chemical group 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000238711 Pyroglyphidae Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229940046533 house dust mites Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000238586 Cirripedia Species 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- -1 alkyl amines Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000011685 brown norway rat Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000009342 ragweed pollen Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000936 topical exposure Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US645672 | 1996-05-14 | ||
| US08/645,672 US5762943A (en) | 1996-05-14 | 1996-05-14 | Methods of treating type I hypersensitivity using monophosphoryl lipid A |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2205231T3 true ES2205231T3 (es) | 2004-05-01 |
Family
ID=24589990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97926449T Expired - Lifetime ES2205231T3 (es) | 1996-05-14 | 1997-05-08 | Procedimiento de tratamiento de la hipersensibilidad de tipo i que utilizan monofosforil lipido a. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5762943A (enExample) |
| EP (1) | EP0914114B1 (enExample) |
| JP (1) | JP4105230B2 (enExample) |
| AT (1) | ATE249824T1 (enExample) |
| AU (1) | AU3121497A (enExample) |
| CA (1) | CA2252604C (enExample) |
| DE (1) | DE69724970T2 (enExample) |
| DK (1) | DK0914114T3 (enExample) |
| ES (1) | ES2205231T3 (enExample) |
| PT (1) | PT914114E (enExample) |
| WO (1) | WO1997042947A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4086928B2 (ja) * | 1997-02-13 | 2008-05-14 | 大日本住友製薬株式会社 | タイプ２ヘルパーｔ細胞型サイトカイン産生選択的抑制剤 |
| GB9706957D0 (en) * | 1997-04-05 | 1997-05-21 | Smithkline Beecham Plc | Formulation |
| GB9724531D0 (en) * | 1997-11-19 | 1998-01-21 | Smithkline Biolog | Novel compounds |
| CA2333578C (en) * | 1998-07-14 | 2010-11-16 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid a |
| EP1113818B1 (en) * | 1998-09-18 | 2006-05-17 | Dynavax Technologies Corporation | METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
| EP1671646A3 (en) * | 1998-09-18 | 2007-08-29 | Dynavax Technologies Corporation | Methods of treating IgE-associated disorders and compositions for use therein |
| GB9820525D0 (en) * | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
| US6649170B1 (en) * | 1999-05-12 | 2003-11-18 | Statens Serum Institut | Adjuvant combinations for immunization composition and vaccines |
| CA2767116A1 (en) | 1999-05-13 | 2000-11-23 | Wyeth Holdings Corporation | Adjuvant combination formulations |
| GB0000891D0 (en) * | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
| BR0110975A (pt) * | 2000-05-19 | 2004-03-23 | Corixa Corp | Tratamento profilático e terapêutico de doenças infecciosas ou outras doenças com compostos à base de mono- e disacarìdeos |
| US20030105032A1 (en) * | 2000-05-19 | 2003-06-05 | Persing David H. | Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds |
| US20030139356A1 (en) * | 2001-05-18 | 2003-07-24 | Persing David H. | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds |
| US6787524B2 (en) | 2000-09-22 | 2004-09-07 | Tanox, Inc. | CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies |
| KR100863368B1 (ko) * | 2000-11-10 | 2008-10-13 | 와이어쓰 홀딩스 코포레이션 | 조합 보조 제제 |
| US20030031684A1 (en) * | 2001-03-30 | 2003-02-13 | Corixa Corporation | Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA) |
| RU2289410C2 (ru) * | 2001-04-04 | 2006-12-20 | Корикса Корпорейшн | Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах |
| GB0120150D0 (en) * | 2001-08-17 | 2001-10-10 | Glaxosmithkline Biolog Sa | Novel compounds |
| DE10359351A1 (de) | 2003-12-16 | 2005-07-21 | Merck Patent Gmbh | DNA-Sequenz und rekombinante Herstellung von Gruppe-4 Majorallergenen aus Getreiden |
| US20060210590A1 (en) | 2005-02-03 | 2006-09-21 | Alk-Abello A/S | Minor allergen control to increase safety of immunotherapy |
| LT2484375T (lt) | 2006-09-26 | 2018-07-10 | Infectious Disease Research Institute | Vakcinos kompozicija, turinti sintetinio adjuvanto |
| WO2011137422A2 (en) * | 2010-04-30 | 2011-11-03 | Apellis Pharmaceuticals, Inc. | Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system |
| EA034351B1 (ru) | 2012-05-16 | 2020-01-30 | Иммьюн Дизайн Корп. | Трехкомпонентная вакцина против впг-2 и способы ее применения |
| HK1214510A1 (zh) | 2013-04-18 | 2016-07-29 | Immune Design Corp. | 用於癌症治疗的gla单一疗法 |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| CA2935722A1 (en) * | 2014-01-21 | 2015-07-30 | Immune Design Corp. | Compositions for use in the treatment of allergic conditions |
| BR112017022585A2 (pt) * | 2015-05-01 | 2018-07-17 | Nitto Denko Corporation | composição de vacina de alergia |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0058021A3 (en) * | 1981-02-06 | 1982-10-27 | Beecham Group Plc | Pharmaceutical compositions |
| US4436727A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4844894A (en) * | 1984-07-12 | 1989-07-04 | Ribi Immunochem Research Inc. | Method of inhibiting the onset of septicemia and endotoxemia |
| US5244663A (en) * | 1987-01-28 | 1993-09-14 | Medibrevex | Therapeutic method against allergy |
| KR900701304A (ko) * | 1988-05-05 | 1990-12-01 | 루이즈 츄이 콜린스 에이미 | 사람 및/또는 동물용 알레르겐 탈감작제 |
| US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US4990336A (en) * | 1989-02-08 | 1991-02-05 | Biosearch, Inc. | Sustained release dosage form |
| JP2838800B2 (ja) * | 1989-09-02 | 1998-12-16 | 株式会社林原生物化学研究所 | 減感作剤 |
| US5286718A (en) * | 1991-12-31 | 1994-02-15 | Ribi Immunochem Research, Inc. | Method and composition for ameliorating tissue damage due to ischemia and reperfusion |
| WO1993015766A1 (en) * | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
-
1996
- 1996-05-14 US US08/645,672 patent/US5762943A/en not_active Expired - Lifetime
-
1997
- 1997-05-08 JP JP54099797A patent/JP4105230B2/ja not_active Expired - Lifetime
- 1997-05-08 DE DE69724970T patent/DE69724970T2/de not_active Expired - Lifetime
- 1997-05-08 EP EP97926449A patent/EP0914114B1/en not_active Expired - Lifetime
- 1997-05-08 AT AT97926449T patent/ATE249824T1/de active
- 1997-05-08 AU AU31214/97A patent/AU3121497A/en not_active Abandoned
- 1997-05-08 WO PCT/US1997/007965 patent/WO1997042947A1/en not_active Ceased
- 1997-05-08 ES ES97926449T patent/ES2205231T3/es not_active Expired - Lifetime
- 1997-05-08 PT PT97926449T patent/PT914114E/pt unknown
- 1997-05-08 DK DK97926449T patent/DK0914114T3/da active
- 1997-05-08 CA CA002252604A patent/CA2252604C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| PT914114E (pt) | 2004-02-27 |
| AU3121497A (en) | 1997-12-05 |
| DE69724970T2 (de) | 2004-07-22 |
| JP4105230B2 (ja) | 2008-06-25 |
| CA2252604A1 (en) | 1997-11-20 |
| EP0914114A1 (en) | 1999-05-12 |
| US5762943A (en) | 1998-06-09 |
| WO1997042947A1 (en) | 1997-11-20 |
| DK0914114T3 (da) | 2003-10-20 |
| ATE249824T1 (de) | 2003-10-15 |
| CA2252604C (en) | 2009-09-08 |
| EP0914114B1 (en) | 2003-09-17 |
| DE69724970D1 (de) | 2003-10-23 |
| JP2000510844A (ja) | 2000-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2205231T3 (es) | Procedimiento de tratamiento de la hipersensibilidad de tipo i que utilizan monofosforil lipido a. | |
| Horner et al. | DNA‐based immunotherapeutics for the treatment of allergic disease | |
| ES2296629T3 (es) | Composiciones adyuvantes inmunologicas acuosas de monofosforil-lipido a. | |
| ES2277413T3 (es) | Formulacion que comprende un antigeno, un adyuvante inductor de una reaccion th-1 y un aminoacido poco soluble en agua, para uso en inmunizacion. | |
| US4455142A (en) | Method of coadministering an antigen and an immunopotentiator | |
| ES2296390T3 (es) | Composicion coadyuvante y procedimiento para su uso. | |
| Francis et al. | Adjuvants for allergen immunotherapy: experimental results and clinical perspectives | |
| JPH07505372A (ja) | ３−ｏ−脱アシル化モノホスホリル脂質ａ含有の肝炎ワクチン | |
| HU229968B1 (hu) | Sztreptokokkusz oltóanyag | |
| Isaka et al. | Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant | |
| ES2328336T3 (es) | Composicion de administracion sublingual de adyuvante glicolipido y antigeno. | |
| ES2369550T3 (es) | Formulación de adyuvante para administración en mucosas. | |
| EP0003833B2 (de) | Antigenderivate, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate | |
| US4158052A (en) | Oil-free adjuvant compositions containing N-acetyl-muramyl-L-alanyl-D-isoglutamine | |
| ES2368731T3 (es) | Composición de vacuna contra la alergia, procedimiento de producción de la misma y uso de la misma en el tratamiento de alergias. | |
| ES2435769T3 (es) | Preparación y utilización de una vacuna bivalente contra la adicción a la morfina y la heroína | |
| AU668088B2 (en) | Pharmaceutical dipeptide compositions and methods of use thereof | |
| ES2347566T3 (es) | Inmunomodulador que comprende celulas enteras de bacterias tsukamurella. | |
| BRPI0621185A2 (pt) | substáncias imunogênicas da mucosa que compreendem um adjuvante a base de ácido poliinosìnico-ácido policitidìlico | |
| US20050002943A1 (en) | Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents | |
| US6187803B1 (en) | Drug preparation for oral administration | |
| Edlmayr et al. | Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases | |
| RU2197989C2 (ru) | ПРИМЕНЕНИЕ Mycobacterium vaccae ДЛЯ РЕГУЛЯЦИИ ПО ТИПУ ОТРИЦАТЕЛЬНОЙ ОБРАТНОЙ СВЯЗИ Th2-АКТИВНОСТИ ИММУННОЙ СИСТЕМЫ | |
| BR112020013381A2 (pt) | combinação de imunoglobulina de plasma e imunoglobulina específica ao antigênio para a modificação do sistema imunológico e o tratamento ou prevenção de doenças alérgicas | |
| JPS6225646B2 (enExample) |